Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Apr 15;17(4):103131.
doi: 10.4251/wjgo.v17.i4.103131.

Intraperitoneal perfusion of endostatin improves the effectiveness and prolongs the prognosis of patients with gastric cancer

Yong Liu  1   2   3 , Hong-Gen Liu  4   5 , Cheng Zhao  4   6
Affiliations
Clinical Trial

Intraperitoneal perfusion of endostatin improves the effectiveness and prolongs the prognosis of patients with gastric cancer

Yong Liu et al. World J Gastrointest Oncol. .

Abstract

Background: Studies on the application of recombinant human endostatin (RH-endostatin) intraperitoneal perfusion in gastric cancer (GC) with malignant ascites are limited.

Aim: To explore the effectiveness, prognosis, and safety of intraperitoneal RH-endostatin perfusion in treating patients with GC and malignant ascites.

Methods: Patients with GC and malignant ascites were divided into the cisplatin intraperitoneal perfusion (control group) group and the cisplatin combined with RH-endostatin intraperitoneal perfusion group (RH-endostatin group). Efficient ascites control, overall survival (OS), quality of life, and adverse events were observed, and possible influencing factors on prognosis outcomes analyzed.

Results: We identified no significant differences in baseline characteristics between the control and RH-endostatin groups. The latter group had higher ascites control rates than the control group. Treatment methods were identified as an independent OS factor. Clinically, RH-endostatin-treated patients had significantly improved OS rates when compared with control patients, particularly in those with small and moderate ascites volumes. Quality of life improvements in control patients were significantly lower when compared with RH-endostatin patients. Adverse events were balanced between the groups.

Conclusion: Overall, intraperitoneal RH-endostatin improved treatment efficacy and prolonged prognosis in patients with GC and malignant ascites. This approach may benefit further clinical applications for treating GC.

Keywords: Cisplatin; Efficacy; Gastric cancer; Malignant ascites; Peritoneal metastasis; Prognosis; Recombinant human endostatin.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: There are no conflicts of interest in this study.

Figures

Figure 1
Figure 1
Flowchart of enrolled patients in the present study. KPS: Karnofsky performance scale.
Figure 2
Figure 2
Survival curve of enrolled patients. A: Survival curve based on different treatment methods; B: Survival curve based on different treatment methods in patients with small ascites volume; C: Survival curve based on different treatment methods in patients with moderate ascites volume; D: Survival curve based on different treatment methods in patients with massive ascites volume.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Zhang J, Qi Z, Ou W, Mi X, Fang Y, Zhang W, Yang Z, Zhou Y, Lin X, Hou J, Yuan Z. Advances in the treatment of malignant ascites in China. Support Care Cancer. 2024;32:97. - PubMed
    1. Huang XZ, Pang MJ, Li JY, Chen HY, Sun JX, Song YX, Ni HJ, Ye SY, Bai S, Li TH, Wang XY, Lu JY, Yang JJ, Sun X, Mills JC, Miao ZF, Wang ZN. Single-cell sequencing of ascites fluid illustrates heterogeneity and therapy-induced evolution during gastric cancer peritoneal metastasis. Nat Commun. 2023;14:822. - PMC - PubMed
    1. Senthil M, Dayyani F. Role of Iterative Normothermic Intraperitoneal Paclitaxel Combined with Systemic Chemotherapy in the Management of Gastric Peritoneal Carcinomatosis. Ann Surg Oncol. 2024;31:694–696. - PMC - PubMed
    1. Bhutiani N, Grotz TE, Concors SJ, White MG, Helmink BA, Raghav KP, Taggart MW, Beaty KA, Royal RE, Overman MJ, Matamoros A, Scally CP, Rafeeq S, Mansfield PF, Fournier KF. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit. Ann Surg Oncol. 2024;31:614–621. - PMC - PubMed
    1. Wahba R, Schmidt T, Buchner D, Wagner T, Bruns CJ. [Surgical treatment of pseudomyxoma peritonei-Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy] Chirurgie (Heidelb) 2023;94:840–844. - PubMed

Publication types

LinkOut - more resources